"We regret that Bo Jesper needs to resign, and we thank him for his valuable contributions to Sobi", says
Sobi
Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on
Investor Relations
Phone +41 79 287 10 51
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-s-chairman-of-the-board-resigns-due-to-health-reasons,c3904500
https://mb.cision.com/Main/14266/3904500/2523662.pdf
(c) 2024 Cision. All rights reserved., source